FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last)	ni Samart	irst)	(Middle)		CRIS	of Earliest	erap	eutics A	<u>Ğ</u> [	CRSP ]	l			k all applica Director Officer ( below)	able)		on(s) to Issu 10% Ow Other (s below) Officer	mer
C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET																		
(Street) CAMBR (City)			02139		4. If Amendment, Date of Original Filed (Month/Day/Year)						Indi ne) X							
(City)	(City) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Trans Date			. Transac			3. Transac Code (In 8)	tion	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		ed (A) or str. 3, 4 an	5. Amour Securitie Beneficia Owned F Reported		s Form (D) or (I) (In on(s)		: Direct Indirect str. 4)	7. Nature of ndirect Beneficial Ownership Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date curity or Exercise (Month/Day/Year) if any		Execution Date	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	le V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Share			Transaction(s) (Instr. 4)			
Stock Option (Right to Buy)	\$58.29	02/18/2022		A		115,000		(1)	0	2/18/2032	Common Shares	115,00	00	\$0.00 115,000		00	D	
Restricted Stock Units	(2)	02/18/2022		A		53,000		(3)		(3)	Common Shares	53,00	0	\$0.00	53,00	0	D	

## **Explanation of Responses:**

- 1. This option was granted on February 18, 2022 with respect to 115,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022.
- 2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- 3. This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.

## Remarks:

/s/ Michael Esposito, attorney-

in-fact

02/22/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.